A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

NCT03964415 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3900

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Ad26.Mos4.HIV
BIOLOGICAL: Clade C and Mosaic gp140 HIV bivalent vaccine
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.